Ilsung Pharm (KO:003120) — Stock Price

₩20450.00 KRW
▲ 0.25% today

Ilsung Pharm (KO:003120) is currently trading at ₩20450.00 KRW, up 0.25% today. Over the past 52 weeks, shares have ranged between ₩18300.00 and ₩28300.00. This page tracks Ilsung Pharm's live share price on the KO exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see 003120 market cap.

Ilsung Pharm (003120) Stock Price Chart — Daily History & Trading Volume

The chart below tracks Ilsung Pharm's daily closing share price and trading volume on the KO exchange over the past year, giving a clear view of recent price momentum and liquidity.

Ilsung Pharm Income Statement — Revenue, Profit & Earnings by Year

Ilsung Pharm's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.

Fiscal Year 20252024202320222021
Total Revenue ₩64.29 Billion ₩69.02 Billion ₩78.05 Billion ₩61.25 Billion ₩42.09 Billion
Cost of Revenue ₩36.41 Billion ₩41.97 Billion ₩41.97 Billion ₩33.31 Billion ₩25.95 Billion
Gross Profit ₩27.88 Billion ₩27.05 Billion ₩36.09 Billion ₩27.94 Billion ₩16.14 Billion
Research & Development ₩494.91 Million ₩354.36 Million ₩588.08 Million ₩1.51 Billion ₩99.08 Million
SG&A ₩21.86 Billion ₩23.07 Billion ₩22.78 Billion ₩14.78 Billion ₩9.15 Billion
Total Operating Expenses ₩70.45 Billion ₩72.26 Billion ₩103.30 Billion ₩59.95 Billion ₩43.89 Billion
Operating Income ₩-6.16 Billion ₩-3.25 Billion ₩-25.25 Billion ₩1.30 Billion ₩-1.80 Billion
EBITDA — — — ₩141.08 Billion ₩1.56 Billion
EBIT — — — ₩1.30 Billion ₩-1.80 Billion
Interest Expense ₩35.40 Million ₩36.22 Million ₩23.87 Million ₩12.63 Million ₩12.63 Million
Income Before Tax ₩2.83 Billion ₩11.16 Billion ₩-21.34 Billion ₩137.97 Billion ₩-1.52 Billion
Income Tax Expense — — — ₩32.73 Billion ₩-155.82 Million
Net Income ₩1.17 Billion ₩13.09 Billion ₩-20.94 Billion ₩105.24 Billion ₩-1.37 Billion

Ilsung Pharm Balance Sheet — Assets, Liabilities & Shareholder Equity

The balance sheet below summarizes Ilsung Pharm's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.

Fiscal Year 20252024202320222021
Total Assets ₩403.01 Billion ₩396.88 Billion ₩419.19 Billion ₩494.42 Billion ₩371.38 Billion
Total Current Assets ₩269.98 Billion ₩270.47 Billion ₩293.94 Billion ₩343.91 Billion ₩279.96 Billion
Cash & Equivalents — — — — —
Short-term Investments ₩105.65 Billion ₩112.05 Billion ₩75.33 Billion ₩27.01 Billion ₩13.24 Billion
Net Receivables ₩16.28 Billion ₩15.09 Billion ₩23.30 Billion ₩16.32 Billion ₩12.58 Billion
Inventory ₩26.50 Billion ₩28.24 Billion ₩31.24 Billion ₩20.64 Billion ₩12.48 Billion
Property, Plant & Equipment — — — ₩92.65 Billion ₩33.11 Billion
Goodwill — — — — ₩0.00
Total Liabilities ₩16.67 Billion ₩11.75 Billion ₩36.44 Billion ₩48.85 Billion ₩25.47 Billion
Total Current Liabilities ₩15.45 Billion ₩10.37 Billion ₩34.89 Billion ₩42.56 Billion ₩20.73 Billion
Long-term Debt — — — — —
Net Debt — — — — —
Total Stockholder Equity ₩386.34 Billion ₩385.13 Billion ₩382.75 Billion ₩445.57 Billion ₩345.91 Billion
Retained Earnings ₩455.24 Billion ₩461.92 Billion ₩459.16 Billion ₩506.89 Billion ₩402.81 Billion

Ilsung Pharm Cash Flow Statement — Operating, Investing & Financing Activities

This cash flow statement breaks down how Ilsung Pharm generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.

Fiscal Year 20252024202320222021
Operating Cash Flow ₩3.88 Billion ₩-4.26 Billion ₩-41.47 Billion ₩-38.97 Billion ₩5.70 Billion
Capital Expenditures ₩2.18 Billion ₩12.09 Billion ₩7.73 Billion ₩62.01 Billion ₩10.93 Billion
Free Cash Flow ₩1.71 Billion ₩-16.34 Billion ₩-49.20 Billion ₩-101.46 Billion ₩-6.91 Billion
Investing Cash Flow — — — ₩266.83 Billion ₩10.43 Billion
Financing Cash Flow — — — ₩-5.74 Billion ₩-1.48 Billion
Dividends Paid ₩-6.82 Billion ₩-10.20 Billion ₩-29.66 Billion ₩1.15 Billion ₩1.15 Billion
Stock-Based Compensation — — — — —
Depreciation ₩3.32 Billion ₩3.62 Billion ₩3.09 Billion ₩3.09 Billion ₩3.07 Billion
Change in Cash ₩10.04 Billion ₩-49.85 Billion ₩-112.83 Billion ₩222.08 Billion ₩14.62 Billion

Ilsung Pharm Earnings History — EPS Actual vs. Analyst Estimates

Track Ilsung Pharm's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.

Report Date EPS Actual EPS Estimate Surprise
Dec 31, 2025 498.57 — —
Sep 30, 2025 50.04 — —
Jun 30, 2025 -604.64 — —
Mar 31, 2025 225.76 — —
Dec 31, 2024 669.60 — —
Sep 30, 2024 1411.28 — —
Jun 30, 2024 -61.89 — —
Mar 31, 2024 -97.81 — —